Program
EA5
A development code.
Its studies are mostly in Myasthenia Gravis · Antiphospholipid Syndrome · Hemoglobinuria, Paroxysmal, led by Shanghai Lanyi Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Lanyi Therapeutics | 43 open or running | phase 1since Nov 20, 2025 | Nov 20, 2025 | Sep 30, 2027phase 1 · NCT07632976 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2025First studies: 2 phase 1 studiesFirst studyNCT07256301, NCT07256288
- May 28, 2026Phase 1 study in Antiphospholipid SyndromeNCT07632976 · 12 enrolled · China
- Sep 1, 2026Phase 1 study in Myasthenia GravisNCT07818291 · 18 planned · China
Ahead
- Sep 30, 2027Primary completion: phase 1 study in Antiphospholipid SyndromeNCT07632976
- Dec 31, 2027Primary completion: phase 1 study in Myasthenia GravisNCT07818291
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07818291Myasthenia Gravis · China | 1 | Not yet recruiting | Dec 31, 2027 | 18 |
| NCT07632976Antiphospholipid Syndrome · China | 1 | Active, not recruiting | Sep 30, 2027 | 12 |
| NCT07256301Hemoglobinuria, Paroxysmal · China | 1 | Recruiting | Aug 31, 2026 | 24 |
| NCT07256288Healthy Volunteers · China | 1 | Completed | Aug 1, 2024 | 28 |
How it is read
Names in the registry
- “EA5”, 7 entries
Codes read as this program: EA5.
Conditions, from the studies’ own filings
- Myasthenia Gravis, 1 study
- Antiphospholipid Syndrome, 1 study
- Hemoglobinuria, Paroxysmal, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.